References
- Spix C, Pastore G, Sankila R, Stiller CA, Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2081–2091.
- De Bernardi B, Gerrard M, Boni L, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol. 2009;27:1034–1040.
- Rubie H, De Bernardi B, Gerrard M, et al. Excellent outcome with reduced treatment in infants with non-metastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol. 2011;29:449–455.
- Gigliotti AR, Di Cataldo A, Sorrentino S, et al. Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry. Eur J Cancer. 2009;45:3220–3227.
- Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–1477.
- Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289–297.
- Pagès PM, Dufour C, Fasola S, et al. Bilateral adrenal neuroblastoma. Pediatr Blood Cancer. 2009;52:196–202.
- Brouard J, Nivot S, Deschrevel G, Duhamel JF. Neonatal Pepper's syndrome with bilateral adrenal tumor. Arch Fr Pediatr. 1990;47:543.